Micrograph News and Research

RSS

The approved dose of ivermectin alone not useful in treating COVID-19

A new paper published on the preprint server medRxiv in April 2020 shows that the use of the already approved drug ivermectin in clinical trials to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)s not feasible. This contradicts earlier reports of its ability to suppress the virus in vitro.

27 Apr 2020

SARS-CoV-2 spike protein discovery could pave way for COVID-19 vaccine

Researchers at the Indian Institute of Technology, Guwahati, have made an important discovery about a viral fusion protein found on the surface of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that could help researchers develop a vaccine.

27 Apr 2020

Rice University looks to ‘trap and zap’ SARS-CoV-2 in wastewater

A team of researchers from Rice University has won a National Science Foundation (NSF) RAPID grant to adapt their wastewater nanotechnology project to help trap and inactivate the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), (which causes COVID-19 disease), in wastewater. This could help public health officials deal with the threat of disease transmission through wastewater.

27 Apr 2020

Recombinant protein produces neutralizing COVID-19 antibodies in primate model

A new study reports the induction of high levels of neutralizing antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus causing the current pandemic of COVID-19. This promising finding was reported on the preprint server bioRxiv on April 2020.

26 Apr 2020

Mapping complex peripheral immune response to severe COVID-19

In a recent article publicly available at medRxiv, researchers from Stanford have presented a single-cell atlas of the peripheral immune response to coronavirus disease (COVID-19), highlighting pertinent immunological features associated with the severe forms of the disease.

26 Apr 2020

Research looks at best ways to tackle coronavirus crisis

A new study published in the journal Frontiers in Microbiology in April 2020 discusses the most attractive approaches among the broad spectrum of experimental and theoretical strategies being worked on to counter the COVID-19 pandemic.

24 Apr 2020

Is the confidence in hydroxychloroquine for the management of COVID-19 justified?

A new review paper published in the preprint open-access journal medRxiv in April 2020 reports that there is not enough evidence to justify the widespread use of the drug hydroxychloroquine (HCQ) in the treatment or prophylaxis of the current COVID-19 illness.

23 Apr 2020

Link between BCG and lower COVID-19 mortality disproved by new analysis

The association between BCG (Bacillus Calmette-Guérin) vaccination and its purported beneficial effect on COVID-19 transmission/mortality rates was challenged in an expert appraisal of Diamond Princess cruise ship data. At the same time, cross-national differences previously reported were shown to be flawed, reports a new medRxiv study.

23 Apr 2020

Genomic sequencing shows COVID-19 spread patterns

Throughout the spread of the virus, genomic sequencing has played a role in epidemiologic tracking of the viral strains carried all over the world. Such strains are traced back to their origin by their unique mutations and help to link remote infections.

22 Apr 2020

Coronavirus has mutated into at least 30 variants

The coronavirus disease (COVID-19) continues to threaten millions of people across the globe, and lockdowns appear set to remain in place in many countries amid rising death tolls, as governments decide whether to extend restrictions aimed at reducing the spread of the virus. Now, a new study reveals that the novel coronavirus has mutated into at least 30 different genetic variants, affecting different parts of the world.

22 Apr 2020

Using community memory to figure out the incubation period for COVID-19

The COVID-19 epidemic that began at the end of 2019 in China’s Wuhan city has now spread to over 185 countries and territories, taking over 177,000 lives out of approximately 2.5 million reported cases. Without either a vaccine or a reliable cure at hand, public health authorities are stretched to contain the virus spread.

22 Apr 2020

Immunity to coronavirus infection may help stem the pandemic

The raging coronavirus pandemic is causing immense fear and uncertainty across the world. One of the most distressing aspects of COVID-19 disease is the seemingly large number of unknowns. These include the burning question of immunity. Does a person who was sick with the COVID-19 and then recovered or was infected without symptoms, have immunity against re-infection?

21 Apr 2020

Difference between flu and novel coronavirus disease

Both influenza and COVID-19 disease are caused by infectious respiratory agents and cause symptoms that can look quite similar. Coronaviruses cause both. So, what’s the difference?

21 Apr 2020

ACE2 receptor expression by SARS-CoV-2 across different animal species

A new report published on the preprint server bioRxiv in April 2020 reports that several species of animals can be infected with relative ease by the SARS-CoV-2 virus that is the causative agent of the currently raging COVID-19 pandemic. This casts much light on the possible natural hosts and routes of transmission of this virus.

20 Apr 2020

ACE2-TMPRSS2 profiling indicates tissue vulnerability to SARS-CoV-2 infection

A new study published in April 2020 on the preprint server bioRxiv reports that the different levels of susceptibility of various organs to viral attack by the SARS-CoV-2 virus causing the huge pandemic of COVID-19 sweeping around the world can be predicted from the level of expression of two molecules, the ACE2 receptor, and the TMPRSS2 protein.

20 Apr 2020

Remdesivir prevents COVID-19 progression to severe pneumonia, animal study shows

A team of scientists at the National Institute of Allergy and Infectious Diseases, which is part of the U.S. National Institutes of Health, has tested the efficacy of remdesivir, a nucleotide analog prodrug with a broad antiviral activity, as a COVID-19 treatment.

20 Apr 2020

Scientists unveil novel coronavirus variants in India

The global coronavirus disease COVID-19 pandemic is ravaging the world, affecting 185 countries and territories and infecting 2.4 million people. Now, a team of scientists aims to shed light on the variants of the novel coronavirus strains in India, showing how changes correspond to its transmission and how it causes disease.

19 Apr 2020

Computer simulations yield promising vaccine candidate against SARS-CoV-2

In a recent study that appeared on a preprint server bioRxiv, scientists from India designed a multi-epitope peptide-based vaccine that predicted high immunogenic response in the population.

19 Apr 2020

Scientists predict how the novel coronavirus spreads in a typical household

A team of scientists recently carried out a study on the transmissibility of the virus in households. Simply put, they’re trying to predict how the virus spreads in a typical family: if one person gets sick, how many others get sick? How sick? How long would it take the family to recover? These are the practical questions this study tries to answer.

17 Apr 2020

Remdesivir drug stops novel coronavirus from replicating

Scientists from the University of Alberta have published findings that the antiviral drug remdesivir prevents replication of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by inhibiting RNA replication. The study, published in April 2020 in the Journal of Biological Chemistry, follows on the heels of earlier reports from the same lab in February, showing the drug's effectiveness against the related Middle East Respiratory Syndrome (MERS) virus.

15 Apr 2020